Drug Profile
Research programme: Zika virus vaccine - Emergent BioSolutions
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Unknown
- Developer Emergent BioSolutions
- Class Synthetic vaccines; Zika virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Zika virus infection
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Zika-virus-infection in USA
- 04 Aug 2016 Preclinical trials in Zika virus infection in USA (unspecified route)
- 27 Jun 2016 Emergent BioSolutions receives a task order from the Biomedical Advanced Research and Development Authority for the development of a Zika virus vaccine